Benitec Biopharma Inc. (BNTC) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low10.6·High10.6
P/FCF
N/A
—
5yr avg: N/A
30Y Low8.8·High8.8
P/B Ratio
↑
4.52
↓-55% vs avg
5yr avg: 10.11
30Y Low1.5·High27.9
ROE
↑
-52.5%
↓+84% vs avg
5yr avg: -332.7%
30Y Low-159%·High19%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BNTC Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Benitec Biopharma Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $416M | $424M | $72M | $6M | $38M | $73M | $32M | $39M | $84M | $65M | $36M |
| Enterprise Value | $319M | $327M | $21M | $4M | $35M | $53M | $23M | $23M | $72M | $52M | $22M |
| P/E Ratio → | -11.56 | — | — | — | — | — | — | 6.71 | — | — | — |
| P/S Ratio | — | — | — | 75.02 | 519.41 | 1237.65 | 333.10 | 3.40 | 183.91 | 144.15 | 104.15 |
| P/B Ratio | 4.52 | 4.35 | 1.52 | 27.85 | 13.16 | 3.65 | 3.16 | 2.32 | 6.08 | 3.93 | 2.57 |
| P/FCF | — | — | — | — | — | — | — | 8.78 | — | — | — |
| P/OCF | — | — | — | — | — | — | — | 8.04 | — | — | — |
P/E links to full P/E history page with 30-year chart
BNTC EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | 49.45 | 474.87 | 906.20 | 236.23 | 2.02 | 157.97 | 114.50 | 64.86 |
| EV / EBITDA | — | — | — | — | — | — | — | 10.57 | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 8.83 | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | 5.20 | — | — | — |
BNTC Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -52.5% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | -408.0% | 87.7% | -108.5% | 290.7% | 96.2% | 27.3% | 53.6% | 70.0% |
| Operating Margin | — | — | — | -25441.3% | -24457.5% | -23044.1% | -8537.1% | 17.7% | -1877.7% | -3536.2% | -7204.2% |
| Net Profit Margin | — | — | — | -26082.7% | -24942.5% | -23528.8% | -8529.9% | 25.3% | -1877.4% | -971.0% | -5340.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -52.5% | -52.5% | -91.7% | -1268.6% | -159.1% | -91.8% | -61.7% | 18.9% | -56.4% | -28.6% | -114.3% |
| ROA | -50.0% | -50.0% | -76.8% | -374.9% | -133.1% | -83.8% | -53.5% | 16.4% | -51.7% | -27.1% | -107.5% |
| ROIC | — | — | — | — | -31507.1% | -1573.6% | -723.6% | 106.2% | -250.2% | -658.4% | -1820.3% |
| ROCE | -57.6% | -57.6% | -94.6% | -971.8% | -152.3% | -88.8% | -60.9% | 13.2% | -56.3% | -104.0% | -154.1% |
BNTC Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $98M exceeds total debt of $849000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 2.77 | 0.28 | 0.01 | 0.04 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.00 | -1.07 | -9.50 | -1.13 | -0.98 | -0.92 | -0.95 | -0.86 | -0.81 | -0.97 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | -7.27 | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -3.58 | — | — | — |
| Interest Coverage | — | — | — | -578.21 | -557.94 | -2266.00 | — | — | — | — | — |
Net cash position: cash ($98M) exceeds total debt ($849000)
BNTC Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Benitec Biopharma Inc.'s current ratio of 54.67x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.94x to 54.67x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 54.67 | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 9.51 | 7.10 | 8.20 | 19.70 | 18.73 |
| Quick Ratio | 54.67 | 54.67 | 10.49 | 0.94 | 1.90 | 15.05 | 9.51 | 7.10 | 8.20 | 19.77 | 18.58 |
| Cash Ratio | 54.24 | 54.24 | 10.33 | 0.62 | 1.60 | 14.44 | 8.63 | 6.00 | 6.33 | 15.53 | 17.61 |
| Asset Turnover | — | — | — | 0.02 | 0.01 | 0.00 | 0.01 | 0.59 | 0.03 | 0.03 | 0.02 |
| Inventory Turnover | 0.93 | — | — | — | — | — | — | — | — | — | 0.93 |
| Days Sales Outstanding | — | — | — | 267.67 | 15.00 | 154.66 | 222.01 | 81.79 | 2426.08 | 2744.36 | — |
BNTC Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Benitec Biopharma Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 14.9% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | 11.4% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $36M | $10M | $1M | $2M | $1M | $240280 | $201592 | $165064 | $137596 | $111616 |
Peer Comparison
Compare BNTC with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BNTCYou | $416M | -11.6 | — | — | — | — | -52.5% | — | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RCKT | $398M | -1.8 | — | — | — | — | -60.3% | -63.2% | — |
 QURE | $1B | -7.0 | — | — | 89.5% | -1166.8% | -207.1% | -50.7% | — |
 SLDB | $551M | -3.6 | — | — | — | — | -109.9% | -120.8% | — |
 DTIL | $96M | -2.1 | — | — | 92.0% | -152.2% | -62.7% | -726.2% | — |
 SRPT | $2B | -2.9 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 ARWR | $11B | -6389.3 | 90.4 | 69.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $2B | -3.6 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 CRSP | $5B | -8.1 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
See BNTC's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BNTC Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BNTC vs KRYS
Side-by-side business, growth, and profitability comparison vs Krystal Biotech, Inc..
Start ComparisonBNTC — Frequently Asked Questions
Quick answers to the most common questions about buying BNTC stock.
What is Benitec Biopharma Inc.'s P/E ratio?
Benitec Biopharma Inc.'s current P/E ratio is -11.6x. The historical average is 6.7x.
What is Benitec Biopharma Inc.'s ROE?
Benitec Biopharma Inc.'s return on equity (ROE) is -52.5%. The historical average is -61.9%.
Is BNTC stock overvalued?
Based on historical data, Benitec Biopharma Inc. is trading at a P/E of -11.6x. Compare with industry peers and growth rates for a complete picture.